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In developing products for rare diseases, statistical chal-
lenges arise due to the limited number of patients available
for participation in drug trials and other clinical research.
Bayesian adaptive clinical trial designs offer the possibil-
ity of increased statistical efficiency, reduced development
cost and ethical hazard prevention via their incorporation
of evidence from external sources (historical data, expert
opinions, and real-world evidence), andflexibility in the spec-
ification of interim looks. In this paper, we propose a novel
Bayesian adaptive commensurate design that borrows adap-
tively from historical information and also uses a particular
payoff function to optimize the timing of the study’s interim
analysis. The trial payoff is a function of howmany samples
can be saved via early stopping and the probability ofmaking
correct early decisions for either futility or efficacy. We cali-
brate our Bayesian algorithm to have acceptable long-run
frequentist properties (Type I error and power) via simula-
tion at the design stage. We illustrate our approach using a
pediatric trial design setting testing the effect of a new drug
for a rare genetic disease.
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1 | INTRODUCTION
The need for more efficient clinical trial methods continues to increase. Developers of new drugs andmedical devices
are under increasing pressure to control development costs, especially in the clinical testing phase. In theU.S., regulators
at the Food and Drug Administration (FDA) have beenmotivated since December 2016 by the 21st Century Cures Act
and corresponding regulatory rule changes in the Prescription Drug User Fee Act (PDUFA) VI. These documents have
encouraged FDA to consider Phase II and even Phase III applications that utilize novel statistical methods that borrow
from previous clinical data and perhaps even real world evidence (RWE) [1, 2, 3].
Bayesian clinical trial designs offer the potential advantages of reduced study sample size, increased statistical
power, and reductions in cost and ethical hazard [4]. In this paper, we propose a Bayesian adaptive statistical approach
[5], implemented using commensurate priors [4], and utilizing a novel “payoff function" to select an optimal time to
performan interim look at the data. OurBayesian adaptive approach gets themost out of available data by (a) permitting
borrowing from adult data in our pediatric setting, and (b) by allowing the study to terminate early (at the interim look)
if the novel treatment emerges as unequivocally better than placebo (“early win"), or fails to deliver someminimum
level of efficacy (“futility"). These features allow reduction of total trial duration, thus reduce cost and ethical hazard.
Statistically, adaptive trials are most easily implemented using a Bayesian framework (see e.g. [6]), since it avoids
problemswith traditional p-values and “alpha-spending functions" (reviewed by e.g. [7]), instead directly computing
the probability that each treatment is effective given the available data (a posterior probability calculation). Bayesian
procedures also more readily permit incorporation of external evidence (such as historical data and expert opinion)
when needed and appropriate.
A specific examplemotivating this research was the consideration of a pediatric trial design to test the effect of a
oral drug for Gaucher disease, a rare genetic disease belonging to the class of lysosomal storage disorders [8]. In 2014,
FDA granted approval for this drug as a first-line treatment for adults with Gaucher disease type 1who have a CYP2D6
extensive, intermediate, or poormetabolizer phenotype based on two pivotal studies [9, 10]. In particular, efficacy in
treatment-naive patients was demonstrated in the placebo-controlled ENGAGE trial [9], which enrolled patients with
Gaucher disease type 1whowere at least 16 years of age, with the primary endpoint being reduction in spleen volume
(percent change frombaseline). In order to extend the label to treatment-naive children (under age 16), a pediatric study
was needed. However, there were significant challenges in conducting an adequately powered placebo-controlled study
in the treatment-naive pediatric population, due to very slow expected enrollment, resulting in a high likelihood that the
trial will be unable to fully enroll enough patients to achieve acceptable power. Wewould also expect challenges to
pediatric patients (especially those assigned to placebo) in remaining compliant with the study protocol.
The questions raised by this example motivate us to consider an alternative, adaptive commensurate study design
tomaximize the information available at an interim analysis (IA). This design cautiously borrows from the adult data
when appropriate, and potentially stops the study after enrolling fewer patients without sacrificing statistical validity. In
the case of our pediatric study setting, it was reasonable from a clinical perspective to assume that the primary endpoint
used tomeasure the treatment effect in adult populations would still be appropriate for pediatric patients, and that the
magnitude of change in the primary endpoint would likely be similar between adults and children in both the placebo
and treatment arms. In this situation, common tomany pediatric study designs [11], the commensurate prior approach
for incorporating information from historical data [12, 13, 14, 15, 16] can be useful .
The IA is highly desirable in the above example, since the fixed sample size designmay require a sample size that is
not realistic, with the result that we cannot finish the study in a realistic period of time. On the other hand, although the
Bayesianmethod allows us to assess posterior probabilities of futility and efficacy continuously as the data accumulate,
due to the significant cost involved in cleaning andmaking the database available for IA, multiple IAs are not desirable.
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Therefore, it’s important to determine an optimal time to perform the single IA that provides themaximum chance of
making a correct early decision. Papers investigating the optimal placement of interim analyses do not appear plentiful
in the literature. Togo and Iwasaki [17] proposed amethod that seeks tominimize the total expected sample size under a
specified treatment effect, and find that, regardless of the effect size, the optimal time for a single IA is at approximately
2/3 of the planned sample size for the O’Brien-Fleming-type and approximately 1/2 for the Pocock-type alpha spending
functions, where the expected sample sizes were calculated under a fixed treatment effect as used for the study power.
They also noted that when the true effect size was better than or worse than the planned treatment effect, the optimal
time would be shifted. In practice, the timing of an interim analysis for non-Bayesian type of studies was typically
chosen in the range of 40-60% of the total sample size based on number of patients needed for safety assessment and
enrollment estimation to allow potential saving with the early stopping. Yet a goal of clinical trials is often to seek to
optimize the tradeoff between costs (e.g., the expected sample size) and benefits (e.g., the correct early futility/efficacy
decisions at IA), along withmany other consideration that go beyond a standard sample size calculation [18].
The Bayesian paradigm is especially promising for constructing our adaptive framework, since it provides a unified
and interpretable language for data collection, inference, and decisionmaking [19]. However, on the Bayesian side, the
literature for investigating optimal IA timing is even sparser. A rare exception is the work of Huang and Fu [20], who use
simulation to estimate the optimal location of a single IA using a utility-based Bayesian adaptive design in a particular
dose-response setting. We hope the new Bayesian designs proposed in this paper can be soon applied in the future
clinical development program in the comparable situations.
The rest of our paper is organized as follows. Section 2 lays out the details of our Bayesian adaptive commensurate
prior approach, along with a step-by-step algorithm for its implementation. Section 3 then gives the results of an
extensive simulation study to check our method’s performance in the pediatric example setting. Our approach is able to
obtain sensible optimal look times that maximize a payoff function that is essentially measures the weighted conditional
probability of early stopping relative to the total sample size expected. Finally, Section 4 summarizes our findings and
offers avenues for future research, including alternate definitions of the payoff function.
2 | STATISTICAL METHODS AND ALGORITHMIC APPROACH
In our approach, we apply Bayesianmethods with a commensurate prior to potentially stop a study at a single interim
analysis. We use early futility and efficacy criteria based on Bayesian posterior probabilities of a treatment difference
reaching pre-specified thresholds [6], after adaptively borrowing information from historical adult study data, depen-
dent on its similarity to data from the current study. We calibrate our Bayesian procedures to have acceptable long-run
frequentist properties (Type I error and power) via computer simulation at the design stage. The optimal timing of the
IA will be evaluated via simulation by assessing a grid of plausible time points, among all decision criteria that meet
certain Bayesian and frequentist properties. This optimization is based on a payoff function that characterizes the
benefit/cost ratio of the decision. The proposed payoff function also introduces a weight parameter that allows expert
input, including level of interest and/or confidence on the new treatment, available budget, and the internal and external
competitive environment.
To formalize ideas, let nk be the sample size for the pediatric study in group k , where k = 1 is the placebo group and
k = 2 is the treatment group. Let n0k be the sample size for the two historical (adult) groups respectively. Since wewill
typically havemuchmore adult data than pediatric, in what followswe set n1 = n2 < n01 = n02. Let n ≡ n1 + n2 be the
maximum total pediatric sample size if the trial runs to completion. We recommend selecting themaximum pediatric
sample size to achieve a reasonable power based on a clinically meaningful target treatment effect, in order to allow the
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study to still have a good chance to achieve its objective in the least favorable case where no information at all can be
borrowed from the adult study data. We propose a trial with a single interim look, after n′ pediatric spleen reductions
have been observed. Let θk be the mean % reduction in spleen volume for children in group k and θ0k be the same
quantities for the two historical (adult) groups respectively. O’Hagan and Stevens [21] introduced the notion of using
two different prior distributions in clinical trial settings: a design prior, a more realistic choice used to evaluate the likely
properties of a design, and an analysis prior, a typically more conservative choice that will actually be usedwhen the data
are observed. Consider the latter choice first; our analysis prior uses a commensurate prior framework [4], and assumes
θk |θ0k ∼ N (θ0k , 1/τk ), and θ0k ∼ N (0,σ20 ), k = 1, 2, (1)
where we assume θ0k follows a vague prior for the adult percent spleen reductions, e.g. σ0 = 100 is known. The
commensurability parameters (precisions) τk are assigned independent hyperpriors, e.g., the conjugate choices τk ∼
G (1/50, 1) as relatively vague Gamma specifications.
Turning to the observed data, suppose we assume thatYk j andY0k j , the observed percent reductions for each
pediatric and adult patient, are also normally distributed, that is,
Yk j
i nd∼ N (θk , 1/ω) andY0k j i nd∼ N (θ0k , 1/ω0) , (2)
where the patient index j runs from 1 to nk or n0k , respectively, andwe again use vague conjugate priors forω andω0;
e.g.,ω,ω0 i i d∼ G (1/100, 1).
We design and calibrate the trial to have acceptable long-run frequentist properties (Type I error and power) for
any given value of n′, and then select the value that maximizes trial payoff (as defined below). Also, our design uses
one interim look to check for early stopping due to success or futility, accounting for commensurability of the adult
and pediatric data, but does not consider adjusting the randomization ratio depending on how many adults we are
“effectively" borrowing. Such an enhancementwould bepossible to add to our design [22, 23]. Finally, wenote that either
posterior or predictive distributions can be used for these calculations. For simplicity, we use the former (implemented
viaMCMC computation in BUGS, R/Stan or SAS) for our interim stopping rules as follows:
Early winner: If at the interim look, the probability that the novel treatment arm (k = 2) is better exceeds some
prespecified probability pU , i.e., if
P (θ2 > θ1 |Dat a) > pU ,
then Arm 2 is declared the early winner and the trial is stopped early. Wemight take pU be a fairly high value, so
early trial termination is permitted only when evidence for an early winner is overwhelming [18].
Final winner: Early winner rules are typically paired with corresponding final winner rules, e.g: If, after all patients have
been randomized and reported results, the probability that the treatment arm is the best exceeds some prespecified
probability p0, i.e., if
P (θ2 > θ1 |Dat a) > p0 ,
then Arm 2 is declared the final winner. If however the treatment arm cannotmeet this criterion, thenwe do not
make a final selection as to “best treatment", andmerely summarize the performance of both treatments. Wemight
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set p0 as a slightly less demanding threshold than the early winner level pU .
Early futility: If at the interim look, the probability that the novel treatment arm (k = 2) is better than someprespecified
minimally tolerable response rate θmin falls below some prespecified probability pL , i.e., if
P (θ2 > θmin |Dat a) < pL ,
then the trial is declared futile and is stopped early (i.e., after just n′ patients). Wemight set θmin as theminimum
reduction in spleen volume from the novel treatment that can be clinically relevant), and take pL fairly small. Thus,
if the treatment cannot muster at least a pL chance of a θmin% reduction in spleen volume at our interim look, we
will give up on the treatment and the trial is stopped early for futility.
Algorithm: In summary, our overall algorithm for given choices of n and n′ is as follows:
1. Fix θ1 = θ2 = 0, so that the null hypothesis is true (no difference in pediatric spleen volume reduction between
treatment and placebo).
2. Use equation (2) with a fix w to generate Monte Carlo pediatric observationsYk j , j = 1, . . . , n′k , k = 1, 2, and
combine with the actual adult observationsY0k j , j = 1, . . . , n0k , k = 1, 2.
3. Perform the interim look at the data, estimating the posterior precision of the pediatric response in each group
using both the pediatric data alone and the full model (commensurate prior with adult historical data); namely,
P r ec(θk |D′) and P r ec(θk |D′,D0), whereD′ andD0 denote the interim pediatric and full adult data, respectively. If
posteriors are being computing usingMCMC, these precisionswould just be the reciprocals of the sample variances
of theG MCMC samples {θ(g )
k
, g = 1, . . . ,G } for the 2 groups and the 2 different models (interim pediatric only vs.
full data).
4. For k=1,2, compute the effective historical sample sizes
EH SS k = min
(
max
[
n0k
(
P r ec(θk |D′,D0)
P r ec(θk |D′) − 1
)
, 0
]
, n0k
)
,
so that EH SS1 + EH SS2 is the total adult effective historical sample size [22]. Check to make sure this is not
unacceptably large (say, more than twice as large as n′, the interim pediatric sample size).
5. Use the early winner and futility rules above to see if the trial can stop now; if so, write this down and skip the next
step.
6. Use (2) with the samew in Step 2 to generate the remaining pediatric observationsYk j , j = n′k + 1, . . . , nk , k = 1, 2,
and then use the “final winner" rule above to see if the trial can now choose a definite winner. Note that this
approach is equivalent to using an appropriately sized Bayesian credible interval (BCI) for the pediatric treatment
effect∆ ≡ θ2 − θ1. For example, with p0 = 0.975, the equivalence would be a 95% equal-tail BCI: if it is totally above
0, conclude treatment is superior to placebo; if it is totally below 0, conclude treatment is inferior to placebo; and if
it contains 0, fail to conclude superiority of either treatment. The equivalence of pU and pL to their corresponding
BCIs can be established respectively.
7. Repeat Steps 2–6 Nr ep times, and estimate the Type I error of our design as
# of treatment early winners + # of treatment final winners
Nr ep
. (3)
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Repeat Steps 2–6 and grid search on the choices of pL , pU , and p0 in the stopping rules for the study designs with
the desired test size (say, 5.0%).
8. Keep θ1 = 0but change θ2 = 20 (or any knownvaluemeet the target efficacy), so that now the alternative hypothesis
is true (clinically significant improvement in pediatric spleen volume reduction on treatment as compared to
placebo). Repeat Steps 2–7 above, estimating the power of our design using equation (3), and check if it is above
the desired level (e.g., 80.0%). If the power is not above the desired level, we can alter the choices of pL , pU , and
p0 in the stopping rules and try again, however, to maintain the procedure’s Type I error calibration we can only
choose pL , pU , and p0 among the study designs with the desired test size obtained in Step 6. (Otherwise, if no design
obtained in Step 6 achieves the desired power, wemight instead need to increase n , or alter the hyperpriors on the
τk so that more strength is borrowed from the historical adult data).
9. Rather than fix θ1 and θ2 as in Steps 1 and 8, repeatedly sample them from a particular design prior, for example
θ1 ∼ N (θ1,des ,σ21,des ) and θ2 ∼ N (θ2,des ,σ22,des ) (4)
for the childrenwhere σ1,des and σ2,des are known, and set θ1,des = 0 and θ2,des = ∆. We again use the actual adult
observations, and to be realistic wemight set∆ smaller than themean observed reduction in adults, to reflect the
plausible situation that the treatment offers a greater benefit to adults than it does to children.
In all cases, we repeat Steps 2–7 above again, estimating themarginal probabilities of early stopping Pˆ under our
design prior, including early futility and early winner under the design prior. The numerator (benefit) of the payoff
function can be defined under both the null hypothesis and alternative hypothesis for optimizing beneficial goals
(i.e., to estimate the marginal probabilities of making correct decisions at IA, including early futility under null
hypothesis and early efficacy under the alternative hypothesis separately). Define
Pˆ1 =
# of early futility stops
Nr ep
underH0 and Pˆ2 = # of treatment early winners
Nr ep
underHa . (5)
Use these quantities to compute the trial payoff as
Payoff = wPˆ1 + (1 −w )Pˆ2
Pˆ n′ + (1 − Pˆ )n , (6)
wherew ∈ (0, 1) is a preselected weight that trades off the two types of decisions in (5). The denominator (cost) can
be explained as the expected sample size of the study design.
An alternative full Bayesian payoff function computes themarginal probabilities of early stopping, early futility and
early efficacy under the design prior. This redefines Pˆ1 and Pˆ2 as
Pˆ1 =
# of early futility stops
Nr ep
and Pˆ2 = # of treatment early winners
Nr ep
both under the design prior , (7)
now averaging over the design prior, and again use these quantities to compute the trial payoff in (6).
10. Repeat all the steps above (Steps 1–9) across a grid of n′ values. Choose the n′ value that maximizes the Payoff as
computed in equation (6). This n′ is optimal under design prior (4), and the resulting design has correctly calibrated
and acceptable Type I error and power by construction.
In the next section, we implement this algorithm and use it to determine the optimal timing for an interim analysis
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in the context of our pediatric study setting.
3 | SIMULATION STUDY
3.1 | Simulation settings
In our simulation study, we implement the Bayesian algorithm proposed in Section 2. To illustrate the method, we
simulated the historical study data hypothetically from a normal distribution with the endpoint being % reduction
in spleen volume. The historical study sample size are assumed to be n01 + n02 = 50, in which n01 = 25 are in the
placebo group and n02 = 25 are in the treated group. The simulated historical data havemean difference∆0 = 25 and
corresponding standard deviation SD = 22. We consider a current pediatric study with planned sample size of 40
(n1 = n2 = 20 per arm). This sample size will provide approximately 80% power (under 5.0%Type I error) to detect a
target treatment difference ofHa : θ2−θ1 = 20without considering interim look or external evidence (i.e. historical data
borrowing in this study). We consider potential IA times after n′ = 0, 4, 8, 12, 16, 20, 24, 28, 32, 36 and 40 enrollments. We
vary the weight asw = 0, 0.5, 0.75, 1, to represent the considerationsmentioned in Section 2. For example, withw = 0,
the benefit (numerator of the payoff function) will represent the probability of an early win when the true treatment
effect is at the target; stopping early for futility is deemed to have no value. In this case, the highest payoff will maximize
the probability of early success at IA when the drug is working (benefit), while controlling the expected sample size
(cost). The use ofw = 0.5will place equal weight on stopping early for a win and stopping early to give up on the drug,
whilew = 0.75 places heavier emphasis on earlier abandonment of an apparently ineffective drug. This may occurs if
the external information suggested less favorable profile of the drug or emergence of a new competitor drugmake the
new treatment less desirable for further development. The use ofw = 1 is extremely unlikely in practice as it will place
no benefit on an early win, andwe present the outcome only for completeness.
We set the null hypothesis and target alternative hypothesis as, respectively,
H0 : θ2 − θ1 = 0
and Ha : θ2 − θ1 = 20 .
We choose a minimal efficacy level of θmin = 15 for defining futility at the interim look. Under our design prior, we
consider four values of themean treatment effect: ∆ = 0, for scenarios in which we expect the new treatment will show
no improved efficacy;∆ = 15, for scenarios in which we expect the treatment will achieveminimal efficacy;∆ = 25, for
scenarios in which we expect the treatment will achieve the same high efficacy as the adult (historical) study; and finally
∆ = 35, for surprising scenarios in whichwe expect the new treatment will achieve even higher efficacy than that seen in
the historical adult study.
3.2 | Simulation results
Figure 1 shows our algorithm controls power at the level of 92% (92.3% − 95.7%)whenwe calibrate Type I error (one-
sided at 5%) by finding the suitable choice of pU where we fix p0 = 0.975 and pL = 0.25. This represents a notable boost
of power (at least 12%) compared to the standard frequentist methodwithout historical data borrowing. Table 1 shows
the amount of effective historical samples borrowed from the historical study under different design priors. Noting that
in general we borrowmore placebo than the treated, since under the design prior, we tend to believe the placebo arms
are similar between adults and pediatrics, since they are both untreated and should have no reduction on spleen volume.
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Yet the amount of borrowing for treated arm highly depends on the specifications of design priors and true treatment
effect; note for example the extensive borrowing from treateds even for later IA times when∆ = 25 in Table 1. If on the
other handwe believe the effects of drug on children are quite different from those in adults (other values of∆ in the
table), we tend to rely less on the historical data.
Figure 2 and Table 2 give our main results for payoff function defined in (5)-(6). Figure 2 presents the values of
payoff functions under different scenarios. It is clear that each estimated payoff curve has amaximal point, which can be
interpreted as the optimal time for an interim analysis. In general, we observe the optimal IA times using the specified
payoff function are within the range of recruiting 40% − 70% of patients, depending on the choices of design priors.
One interesting perspective is that when∆ = 15, in which we expect the treatment only achievesminimal efficacy, the
study design provides the latest IA time compared to other scenarios. This is not surprising as under this marginal case
where the current study achieves onlyminimal efficacy, more data (longer waiting time) is needed in order tomake a
clear decision regarding early wins and losses. That is, this is the case that is most difficult for our commensurate prior
framework to handle, as the decisionwhether or not to borrow is not clear-cut. In contrast, under the surprised high
efficacy scenario (∆ = 35), we observe the earliest optimal IA timing, reflecting the investigator’s high confidence in
the treatment’s effectiveness in the current pediatric trial. The no efficacy (∆ = 0) and high efficacy (∆ = 25) scenarios
provide roughly identical optimal IA timing, yet it’s worth noting that the stoppingmechanisms of IA are different: under
no efficacy, early futility dominates the IA decision, while under high efficacy, the early stops are due to early winners.
Table 2 also illustrates the impact of the weightw on our pediatric study design. We see the optimal IA time is
relatively insensitive to the choice ofw , likely since the early win and early futility probabilities are bothmonotonically
increasing as the IAmoves later, and they do this at roughly comparable rates in this example. We do still see a slight
trend towards earlier optimal times whenw is larger, which corresponds to our placing greater importance on early
stopping for futility. Overall, the insensitivity tow is something of a relief, since its choice is somewhat subjective and
thus difficult in practice. However, caution needs to be paid that in certain scenarios, when the rates of change over
time in probabilities of early win and early futility are not similar, the choice ofw may have larger impact on the optimal
IA timing, and then a careful choice ofw need to bemade based on external information. The results of alternative full
Bayesian payoff function are presented in Appendix A1.
Figure 3plots the expected sample size for the implementations of our study under different design priors. Expected
sample size was defined as the expectation of sample size as we either conduct the IA and then stop, or conduct the
IA and then continue to recruit more patients until the completion of study. The finding is that theminimal expected
sample size appears if we conduct the interim analysis when have recruited 30% − 40%patients. Our findings, under a
Bayesian adaptive design, shows the timing of minimizing expected sample size appears earlier than those shown in
Togo and Iwasaki [17], likely due to the information borrowed from the historical data. However, as demonstrated in
Section 2, minimizing the expected sample size is not necessary to be the only criterion for finding optimal IA timing.
Rather, a view towardmaximizing a payoff function that characterizes the benefit/cost ratio is used in our Bayesian
adaptive design. Under the optimal IA timing obtained by maximizing our specified payoff function, 22.6% − 56.4%
savings in expected sample size were observed. This outperforms the study designs presented in [17], which found
18% − 22% savings in sample size with a single IA. Again, the reason is our Bayesian adaptive design effectively borrows
from historical information. We also note that our simulations reveal enormously largerMonte Carlo standard errors
(SEs) associated with the expected sample size estimation for early IA times (left side of Figure 3), yet the SEs shrink to 0
as IA time increases, reflecting the fact that later IAs provide progressivelymore accurate estimation of cost as they
progress toward full enrollment.
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4 | DISCUSSION AND FUTURE WORK
In this paper, we have used a Bayesian commensurate prior formulation to design a clinical trial with an optimally placed
single interim look. Our goal was tomove beyond simple optimality criteria that involve only overall expected sample
size to those that actually measure not just the savings resulting from persons not enrolled in the study, but gains to the
sponsor arising frommaking a correct decision as soon as possible. While the goal of an optimally designed clinical trial
is to be able to declare study success as soon as possible when the drug is working, it’s also important to stop the trial
as soon as possible when the drug is not working. The use of weight in the payoff function allows the project team to
assess the relative importance of these two actions and reach to an ethical decision based on existing information. Also,
since the design has controlled both Type I and Type II errors overall, the proposed payoff function was intended to
maximize the chance of making a “weighted" correct decision as high as possible and as early as possible.
Our findings suggest optimal IA times tended to be different from the optimal time based on cost alone (when
the expected sample size is the smallest). The optimal timemay be earlier when the treatment effect is unequivocal
(either very small or very large), or when greater importance is placed on early stopping for futility (higherw values). By
contrast, equivocal treatment effects (i.e., close to those deemedminimally clinically significant) or a higher emphasis on
early stopping for efficacy (the “early winner") lead to later optimal IA times.
Our payoff function (6) resulted from a hybrid of Bayesian and frequentist ideas, which we do not view as inap-
propriate in a field wheremethods that are formally Bayesian but also required to have good frequentist properties
are routinely used. Unlike the existingmethods which calculate cost only based on a fixed alternative hypothesis, the
current estimate of cost (denominator) based on different Bayesian prior allows a more realistic estimation of the
cost. For an actual trial design, the expected cost should be assessed under all possible scenarios (based on existing
knowledge) to assess their impact on optimal IA timing.
Still, while useful, our payoff function is fairly adhoc, namely throughequation (6)where Pˆ1 = (# of early futility stops)/Nr ep
is an estimate of the probability of an “early loss", Pˆ2 = (# of treatment early winners)/Nr ep is a corresponding estimate
of the probability of an “early win", Pˆ is the probability of early stopping for any reason, andw ∈ (0, 1) is a weight that
trades off these two early stop probabilities.
Suppose we define twomore Bayesian posterior probability estimates [24],
Pˆ3 =
# of treatment late winners
Nr ep
and Pˆ4 = 1 −
3∑
k=1
Pˆk =
# of treatment late losers
Nr ep
.
Let us now think of gain and cost on a purely financial (i.e., dollar) scale. Obviously wewould need help from the trial
sponsor to do this, but we could consider a range of possibilities. Define
Gain(early loss) = a1, Gain(late loss) = a2 < a1,
and Gain(early win) = b1, Gain(late win) = b2 < b1 .
We might take a1 = 0, so that the “gain" from a late loss a2 is actually negative, corresponding to the financial loss
associated with having to postpone development of other drugs while wewaited for this one to fail. Similarly, we would
surely take b1 > 0, but would also take 0 < b2 < b1, due to themissed opportunity to sell the drug while wewaited for
the trial to run to completion.
Next, let C be the trial’s per-patient cost. Then we would have Cost(early loss) = Cost(early win) = Cn′, and
Cost(late loss) = Cost(late win) = Cn, since patients cost the same regardless of whether we win or lose. Thus the
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Bayesian expected net gain for the trial is:
E(Gain – Cost) = Pˆ1a1 + Pˆ2b1 + Pˆ3b2 + Pˆ4a2 − C [(Pˆ1 + Pˆ2)n′ + (Pˆ3 + Pˆ4)n] .
Once again, we could choose the location of the IA tomaximize this posterior expected net gain, instead of the Payoff
function in (6). We hope such an investigation will be the subject of a futuremanuscript.
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F IGURE 1 IA timing (%) vs Type I error and type II error. We calibrate type I error (one-sided at the size of 5.0%) by
grid searching the suitable pu value and fix p0 = 0.975 and p l = 0.25. We show by choosing suitable stopping rules at the
design stage, the type II error are also controlled at the level of 8.0% (4.3% − 7.7%), which is equivalent to 92.3% − 95.7%
power. The grey dashed line represents the level of 8.0%.
TABLE 1 Effective historical sample sizes (EHSS) borrowed from historical study at interim look (Placebo/Treated)
IA time ∆ = 0 ∆ = 15 ∆ = 25 ∆ = 35
30% 17.81 / 6.02 17.97 / 14.99 17.81/ 17.99 17.89/ 14.77
40% 17.08 / 3.76 17.16 / 13.18 17.13/ 17.28 17.12/ 12.93
50% 15.98 / 2.52 16.18 / 11.45 16.29/ 16.41 16.12/ 11.19
60% 15.07 / 1.87 15.17 / 10.03 15.37/ 15.32 15.16/ 9.61
70% 14.19 / 1.60 14.14 / 8.62 14.36 / 14.46 14.25 / 8.46
80% 13.24 / 1.36 13.26 / 7.56 13.62 / 13.50 13.29 / 7.50
90% 12.55 / 1.21 12.49 / 6.52 12.76 / 12.63 12.51 / 6.62
WU ET AL. 13
0.
0
0.
5
1.
0
1.
5
w=0
IA timing (%)
Pa
yo
ff
∆=0
∆=15
∆=25
∆=35
0 20 40 60 80 100
0.
0
0.
5
1.
0
1.
5
w=0.5
IA timing (%)
Pa
yo
ff
∆=0
∆=15
∆=25
∆=35
0 20 40 60 80 100
0.
0
0.
5
1.
0
1.
5
w=0.75
IA timing (%)
Pa
yo
ff
∆=0
∆=15
∆=25
∆=35
0 20 40 60 80 100
0.
0
0.
5
1.
0
1.
5
w=1
IA timing (%)
Pa
yo
ff
∆=0
∆=15
∆=25
∆=35
0 20 40 60 80 100
F IGURE 2 IA timing (%) vs Payoff. Each panel represents the values of payoff function with respect to different
weightsw = 0, 0.5, 0.75, 1. IA timing under different design prior with effect size: 1)∆ = 0, no efficacy, 2)∆ = 15, at
minimal efficacy, 3)∆ = 25, high efficacy, and 4)∆ = 35, surprised high efficacy.
TABLE 2 Optimal IA timing chosen under different choices of design priors and choices of weights in the payoff
effect size w = 0 w = 0.5 w = 0.75 w = 1
0 20 (50%) 20 (50%) 20 (50%) 20 (50%)
15 28 (70%) 28 (70%) 24 (60%) 24 (60%)
25 20 (50%) 20 (50%) 20 (50%) 20 (50%)
35 16 (40%) 16 (40%) 16 (40%) 16 (40%)
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F IGURE 3 IA timing (%) vs Expected sample size. Expected sample size was defined as the expectation of sample
size as we either conduct the IA and then stops or conduct the IA and then continue to recruit patients until the
completion of the study. Under the optimal IA timing obtained byminimizing our specified payoff, 22.6% − 56.4% saves
of expected sample size were observed.
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APPEND IX
A1 | Fully Bayesian payoff function
In this appendix, we include the simulation results for our fully Bayesian payoff function defined in (7). These results are
given in Figure A1 and Table A1. Interestingly, although the shapes of payoff curves change dramatically, the optimal
IA times chosen by the two payoff functions are generally comparable. In particular, we still see the latest optimal IA
times whenwe expect the treatment to achieve only minimal efficacy, and the earliest optimal IA times whenwe expect
very high efficacy. Almost flat payoff curves are observed for the weightw = 0 under design prior corresponding to no
efficacy, and for the weightw = 1 under the design prior corresponding to high or very high efficacy. This is because
under such scenarios, the payoff function only rewards the early stopping reason that is unlikely to happen (e.g., under
the design prior with no efficacy, an early win would be very unusual).
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F IGURE A1 IA timing (%) vs Full Bayesian Payoff. Each panel represents the values of payoff function with respect
to different weightsw = 0, 0.5, 0.75, 1. IA timing under different design prior with effect size: 1)∆ = 0, no efficacy, 2)
∆ = 15, at minimal efficacy, 3)∆ = 25, high efficacy, and 4)∆ = 35, surprised high efficacy.
A2 | Additional data tables
We also include four tables (Table A2-A5) that give detailed results from our simulation study under the four true states
of nature (∆ = 0, 15, 25, and 35). Information from these tables was used in the construction of the figures in themain
paper.
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TABLE A1 Optimal IA timing chosen under different choices of design priors and choices of weights in the payoff
effect size w = 0 w = 0.5 w = 0.75 w = 1
0 16 (40%) 20 (50%) 20 (50%) 20 (50%)
15 32 (80%) 32 (80%) 28 (70%) 24 (60%)
25 20 (50%) 20 (50%) 20 (50%) 4 (10%)
35 16 (40%) 16 (40%) 16 (40%) 0 (0%)
TABLE A2 Results under surprised high efficacy design prior (∆ = 35). P1 and P2 are themarginal probabilities of
early futility under null hypothesis and early efficacy under alternative hypothesis respectively. IA_stop represents the
probability of stopping the study at IA. pU , pL and p0 are early winner rule, final winner rule and early futility rule
respectively.
IA time P1 P2 IA_stop Type I error Power pU pL p0 EHSS (Placebo/Treated)
0 0.13 0.10 0.21 0.052 0.923 0.990 0.250 0.975 20.96 / 20.58
4 0.23 0.15 0.35 0.050 0.923 0.990 0.250 0.975 20.19 / 19.56
8 0.42 0.29 0.63 0.049 0.927 0.992 0.250 0.975 18.87 / 17.01
12 0.58 0.47 0.84 0.051 0.929 0.990 0.250 0.975 17.89 / 14.77
16 0.69 0.62 0.94 0.051 0.932 0.986 0.250 0.975 17.12 / 12.93
20 0.79 0.72 0.98 0.049 0.933 0.984 0.250 0.975 16.12 / 11.19
24 0.84 0.79 0.99 0.048 0.940 0.982 0.250 0.975 15.16 / 9.61
28 0.88 0.85 1.00 0.050 0.947 0.978 0.250 0.975 14.25 / 8.46
32 0.91 0.90 1.00 0.049 0.950 0.974 0.250 0.975 13.29 / 7.50
36 0.93 0.94 1.00 0.052 0.956 0.968 0.250 0.975 12.51 / 6.62
40 0.94 0.96 1.00 0.050 0.957 0.966 0.250 0.975 11.61 / 5.86
TABLE A3 Results under high efficacy design prior (∆ = 25). P1 and P2 are themarginal probabilities of early futility
under null hypothesis and early efficacy under alternative hypothesis respectively. IA_stop represents the probability of
stopping the study at IA. pU , pL and p0 are early winner rule, final winner rule and early futility rule respectively.
IA time P1 P2 IA_stop Type I error Power pU pL p0 EHSS (Placebo/Treated)
0 0.13 0.10 0.13 0.052 0.923 0.990 0.250 0.975 21.09 / 20.83
4 0.23 0.15 0.22 0.050 0.923 0.990 0.250 0.975 20.20 / 20.04
8 0.42 0.29 0.41 0.049 0.927 0.992 0.250 0.975 18.75 / 18.64
12 0.58 0.47 0.62 0.051 0.929 0.990 0.250 0.975 17.81 / 17.99
16 0.69 0.62 0.79 0.051 0.932 0.986 0.250 0.975 17.13 / 17.28
20 0.79 0.72 0.87 0.049 0.933 0.984 0.250 0.975 16.29 / 16.41
24 0.84 0.79 0.92 0.048 0.940 0.982 0.250 0.975 15.37 / 15.32
28 0.88 0.85 0.96 0.050 0.947 0.978 0.250 0.975 14.36 / 14.46
32 0.91 0.90 0.98 0.049 0.950 0.974 0.250 0.975 13.62 / 13.50
36 0.93 0.94 0.99 0.052 0.956 0.968 0.250 0.975 12.76 / 12.63
40 0.94 0.96 0.99 0.050 0.957 0.966 0.250 0.975 11.75 / 11.74
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TABLE A4 Results under moderate efficacy design prior (∆ = 15). P1 and P2 are themarginal probabilities of early
futility under null hypothesis and early efficacy under alternative hypothesis respectively. IA_stop represents the
probability of stopping the study at IA. pU , pL and p0 are early winner rule, final winner rule and early futility rule
respectively.
IA time P1 P2 IA_stop Type I error Power pU pL p0 EHSS (Placebo/Treated)
0 0.13 0.10 0.10 0.052 0.923 0.990 0.250 0.975 20.92 / 20.26
4 0.23 0.15 0.15 0.050 0.923 0.990 0.250 0.975 20.14 / 19.46
8 0.42 0.29 0.25 0.049 0.927 0.992 0.250 0.975 18.76 / 16.86
12 0.58 0.47 0.37 0.051 0.929 0.990 0.250 0.975 17.97 / 14.99
16 0.69 0.62 0.51 0.051 0.932 0.986 0.250 0.975 17.16 / 13.18
20 0.79 0.72 0.61 0.049 0.933 0.984 0.250 0.975 16.18 / 11.45
24 0.84 0.79 0.68 0.048 0.940 0.982 0.250 0.975 15.17 / 10.03
28 0.88 0.85 0.75 0.050 0.947 0.978 0.250 0.975 14.14 / 8.62
32 0.91 0.90 0.82 0.049 0.950 0.974 0.250 0.975 13.26 / 7.56
36 0.93 0.94 0.88 0.052 0.956 0.968 0.250 0.975 12.49 / 6.52
40 0.94 0.96 0.90 0.050 0.957 0.966 0.250 0.975 11.54 / 5.82
TABLE A5 Results under no efficacy design prior (∆ = 0). P1 and P2 are themarginal probabilities of early futility
under null hypothesis and early efficacy under alternative hypothesis respectively. IA_stop represents the probability of
stopping the study at IA. pU , pL and p0 are early winner rule, final winner rule and early futility rule respectively.
IA time P1 P2 IA_stop Type I error Power pU pL p0 EHSS (Placebo/Treated)
0 0.13 0.10 0.15 0.052 0.923 0.990 0.250 0.975 20.86 / 18.89
4 0.23 0.15 0.26 0.050 0.923 0.990 0.250 0.975 20.18 / 16.93
8 0.42 0.29 0.44 0.049 0.927 0.992 0.250 0.975 18.66 / 10.36
12 0.58 0.47 0.60 0.051 0.929 0.990 0.250 0.975 17.81 / 6.02
16 0.69 0.62 0.72 0.051 0.932 0.986 0.250 0.975 17.08 / 3.76
20 0.79 0.72 0.82 0.049 0.933 0.984 0.250 0.975 15.98 / 2.52
24 0.84 0.79 0.87 0.048 0.940 0.982 0.250 0.975 15.07 / 1.87
28 0.88 0.85 0.93 0.050 0.947 0.978 0.250 0.975 14.19 / 1.60
32 0.91 0.90 0.96 0.049 0.950 0.974 0.250 0.975 13.24 / 1.36
36 0.93 0.94 0.98 0.052 0.956 0.968 0.250 0.975 12.55 / 1.21
40 0.94 0.96 0.99 0.050 0.957 0.966 0.250 0.975 11.46 / 1.15
